Wells Fargo & Company Trevena Inc Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.16 - $100.0 $7 - $4,700	47 Added 1.32%	3,605 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.2 - $0.5 $7,236 - $18,090	-36,181 Reduced 91.05%	3,558 $1,000
Q1 2022 May 16, 2022	SELL	$0.41 - $0.63 $26,020 - $39,982	-63,465 Reduced 61.49%	39,739 $21,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.29 $10,307 - $23,327	18,083 Added 21.24%	103,204 $60,000
Q3 2021 Nov 15, 2021	BUY	$1.11 - $1.7 $78,540 - $120,286	70,757 Added 492.6%	85,121 $105,000
Q2 2021 Aug 16, 2021	SELL	$1.46 - $2.25 $12,655 - $19,503	-8,668 Reduced 37.63%	14,364 $25,000
Q1 2021 May 13, 2021	SELL	$1.77 - $2.93 $280,987 - $465,137	-158,750 Reduced 87.33%	23,032 $42,000
Q4 2020 Feb 09, 2021	BUY	$2.13 - $3.26 $273,031 - $417,879	128,184 Added 239.16%	181,782 $389,000
Q3 2020 Nov 05, 2020	SELL	$1.53 - $3.13 $5,899 - $12,069	-3,856 Reduced 6.71%	53,598 $161,000
Q2 2020 Aug 13, 2020	SELL	$0.48 - $1.75 $23,693 - $86,383	-49,362 Reduced 46.21%	57,454 $86,000
Q1 2020 May 14, 2020	BUY	$0.56 - $0.97 $59,816 - $103,611	106,816 New	106,816 $60,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $313M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.